Imprint

Website operator / Responsible entity

MetrioPharm AG

Zurich
Switzerland

Web: www.metriopharm.com

E-mail: info@metriopharm.com

Commercial Register Number: CHE-109.856.841

Source disclosures for the images used on the website www.metriopharm.com

Source disclosures for the images used on the website www.blog.metriopharm.com

News

MetrioPharm Announces Changes to its Board of Directors - 2025-Sep-04

Dr. Stephan Rietiker and Dr. Harald Fricke have stepped down with immediate effect. Jörg Gruber appointed as new Chairman of the Board of Directors.

» more

Investor Relations

Investor-Newsletter QIV 2025 - 2025-Dec-22

Key progress in dose selection and safety, EMA Orphan Drug Designation, How MP1032 works in the body, Manufacturing and independence, Acknowledgements

» more

Please find our corporate slide-deck as download here:
» MetrioPharm corporate slide-deck

The iMPact project is one of six initiatives selected by the European Commission to work on drug candidates for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19.
» Find out more in the iMPact project film